Measles mumps and rubella virus vaccine (Priorix)

Drug Profile

Measles mumps and rubella virus vaccine (Priorix)

Alternative Names: 209762; GSK-209762; MMR vaccine - Bio-Manguinhos; MMR vaccine - GlaxoSmithKline; Priorix

Latest Information Update: 03 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Measles vaccines; Rubella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Measles; Mumps; Rubella

Most Recent Events

  • 26 Oct 2016 Immunogenicity and adverse events data from a phase III trial in Rubella, Measles and Mumps released by GlaxoSmithKline
  • 01 Jul 2016 The Immunobiological Technology Institute and GlaxoSmithKline complete a phase III trial for Measles, Mumps and Rubella (In infants, Prevention) in Brazil (NCT01991899)
  • 01 Dec 2015 GlaxoSmithKline completes a phase III trial in Measles, mumps and rubella (in infants, prevention) in Estonia, Finland, Puerto Rico, Spain and USA (NCT02184572)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top